New Ionizable Lipid Library Suitable for Multiple Organ Targeting Derived From High Throughput Combinatorial Synthesis and Screening

Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue/cell).

Researchers

Daniel Anderson / Idris Raji / Akiva Gordon / Bowen Li

Departments: Department of Chemical Engineering, Chemical Engineering
Technology Areas: Artificial Intelligence (AI) and Machine Learning (ML) / Biotechnology: DNA & RNA Editing / Drug Delivery: Microparticles & Nanoparticles / Therapeutics: Nucleic Acids

  • ionizable lipids for multiple organ targeting
    United States of America | Published application

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies